FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/06/068310 [Registered on: 04/06/2024] Trial Registered Prospectively
Last Modified On: 22/05/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Other (Specify) [Nutrition intervention]  
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Effect of Consumption of Millet based Diet in Patients With NAFLD  
Scientific Title of Study   Effect of Consumption of Millets Based Diet on, Clinical Characteristics, Metabolic Profile, and Gut Microbiome in Patients With Non-alcoholic Fatty Liver Disease  
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Nida athar 
Designation  Senior Research Fellow 
Affiliation  Institute of Liver & Biliary Sciences 
Address  D1 ilbs, D-1, Vasant Kunj Rd, Ghitorni, New Delhi, Delhi 110070
D1 ilbs, D-1, Vasant Kunj Rd, Ghitorni, New Delhi, Delhi 110070
New Delhi
DELHI
110024
India 
Phone  8601079163  
Fax    
Email  nidaathar.20@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Jaya Joy Benjamin 
Designation  Associate Professor, Clinical Nutrition at the Institute of Liver and Biliary Sciences (ILBS)  
Affiliation  Institute of Liver & Biliary Sciences 
Address  Department of Clinical Nutrition, D-1 Vasant Kunj, Institute of Liver & Biliary Sciences

New Delhi
DELHI
110070
India 
Phone  9540951081  
Fax    
Email  jayabenjaminilbs@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Jaya Joy Benjamin 
Designation  Associate Professor, Clinical Nutrition at the Institute of Liver and Biliary Sciences (ILBS)  
Affiliation  Institute of Liver & Biliary Sciences 
Address  Department of Clinical Nutrition, D-1 Vasant Kunj, Institute of Liver & Biliary Sciences

New Delhi
DELHI
110070
India 
Phone  9540951081  
Fax    
Email  jayabenjaminilbs@gmail.com  
 
Source of Monetary or Material Support  
ICAR-IIMR 
 
Primary Sponsor  
Name  ICAR-IIMR 
Address  Himayat Sagar Rd, near Andhra Bank, Hanuman Nagar, Rajendranagar mandal, Hyderabad, Telangana 500030 
Type of Sponsor  Research institution 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Jaya Benjamin  Institute of Liver & Biliary Sciences  D1 ilbs, D-1, Vasant Kunj Rd, Ghitorni, New Delhi, Delhi 110070
South
DELHI 
8601079163

nidaathar.20@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K760||Fatty (change of) liver, not elsewhere classified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Group A-Normal Diet group  This group would receive standard nutritional counselling with customized diet providing 20-25 Kcal/Kg and 1.0 gm protein/kg ideal body wt/day. 15-20% of the total calories as proteins, 50-60% of carbohydrates (Main Source: Wheat, Rice, Oats) and 25-30% of fats.  
Intervention  Group b-millets diet  This group would receive standard nutritional counselling, customized diet providing 20-25 Kcal/Kg and 1.0 gm protein/kg ideal body wt/day. 15-20% of the total calories as proteins, 50-60% of carbohydrates (Main Source: Jowar flakes/jowar millet vermicelli/jowar roti) and 20-25% of fats. 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1. Recently diagnosed consenting adults with NAFL (steatotosis) of any grade with or without features of metabolic syndrome 
 
ExclusionCriteria 
Details  Individuals who had been hospitalised with complications of Diabetes mellitus, Chronic Kidney disease, Hypertension in the previous 6 months
Those with intake of antibiotics within last month
Seriously ill and bed ridden patients
Patients with viral hepatitis
Pregnant & lactating women
Patients with significant alcohol consumption
Patients having chronic inflammatory bowel disease or any chronic and autoimmune diseases will be excluded
Patients with NAFLD with associated hypertriglyceridemia that requires administration of statins 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Change in hepatic steatosis as assessed by fibroscan, ultrasound (change in the CAP, LSM)  3 months 
 
Secondary Outcome  
Outcome  TimePoints 
Change in lipid parameters as assessed by blood lipid profile test  3 months 
Change in blood sugar as assessed by blood fasting glucose, serum insulin & HbA1c  3 months 
Change in liver enzymes as assessed by liver function tests  3 months 
Change in Nutritional status as assessed using bioelectrical impedence analysis  3 months 
Change in gut microbiota   3months 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   10/06/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

With NAFLD fast rising its ranks in becoming a major non communicable disease in India and across the globe, this study aims at primary prevention of the condition. NAFLD is a spectrum of diseases characterised by the deposition of fat within hepatocytes and is a precursor of liver inflammation. Global estimates peg the prevalence to be around 30 to 40%, but there are not many studies which have documented the prevalence in India. With the epidemiological transition, the cases of NAFLD are also on a rise as metabolic syndrome is an important risk factor.

It is apparent that the westernized way of our lifestyle especially the junk food culture comprising of super portions of loads of calories, sugars and salts is the main driver of this nutritional pandemic. The traditional diets in India were rich in fruits and vegetables, low in simple carbohydrates and high in fibre. Cereals are the main source of calories in any diet, forming the base of the food pyramid. Managing our cereals from being refined to the more complex ones being rich in fibre, protein and good quality fat could be a major player in the whole game of dietary modifications not just therapeutically but also prophylactically. Hence our therapeutic focus should be in increasing the consumption of cereals that are not only high in fibre, low in carbohydrates but also that have the potential to modulate the intestinal bacterial ecology to a more favourable type thus helping in intensifying the effects of overall dietary modifications.

Gut microbiota is currently explored for its role in NAFLD and there are gaps in knowledge which preclude having therapeutic strategies through its modulation. Millets, which were once considered to be poor man’s diet are now becoming a part of the plate more frequently, especially for its unique nutritive content, with increased fiber, low carbohydrates, high protein and good quality fats. The processing methods may alter glycemic responses. Thus, the present study is proposed to look into the effect of millet based diets in reduction of hepatic steatosis and the resultant alterations in the gut microbiota

 
Close